Foley Hoag Represents GreenLight Biosciences in Closing $102 Million Series D Funding Round
June 22, 2020
Foley Hoag LLP represented GreenLight Biosciences, a Boston, Massachusetts-based RNA vaccine and drug developer, in closing its $102 million Series D funding round led by Morningside Ventures. S2G Ventures, Cormorant Asset Management, Continental Grain Company, Fall Line Capital, Tao Capital Partners, Baird Capital, MLS Capital Fund II, Lewis and Clark AgriFood, and Lupa Systems also joined the round. The funding will be used to expand production and accelerate development and commercialization of GreenLight’s pipeline of products.
GreenLight develops sustainable solutions to address some of the biggest issues facing our planet today. The company's RNA-based vaccines offer tremendous potential to address pandemics like COVID-19, because of shorter preclinical development times compared to traditional vaccines. Its pipeline of RNA-based agricultural products will help farmers create greener, cleaner crops by precisely targeting a specific pest with non-toxic biocontrols, and without harming beneficial insects or leaving residues in the soil or water.
About Foley Hoag LLP
Foley Hoag provides innovative, strategic legal services to public, private and government clients across the globe. We have premier capabilities in the life sciences, healthcare, technology, energy, professional services and private funds fields, and in cross-border disputes. The diverse backgrounds, perspectives and experiences of our lawyers and staff contribute to the exceptional senior level service we deliver to clients ranging from startups to multinational companies to sovereign states. For more information, visit www.foleyhoag.com or follow @FoleyHoag on Twitter.